Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
Bilici A, Koca S, Karaagac M, Aydin SG, Eraslan E, Kaplan MA, Ocak B, Goksu SS, Paydas S, Akgul F, Derin S, Ergun Y, Yekeduz E, Erol C, Ozyukseler DT, Demiray AG, Karaca M, Guc ZG, Menekse S, Cinkir HY, Gumusay O, Sakin A, Ozkul O, Demir H, Erdem D, Besiroglu M, Unal OU, Acar R, Koral L, Sahin S, Sakalar T, Bahceci A, Ozveren A, Gunaydin UM, Seker MM, Sunar V, Dal P, Artac M, Turhal S. Bilici A, et al. Among authors: yekeduz e. J Cancer Res Clin Oncol. 2023 Sep;149(11):8243-8253. doi: 10.1007/s00432-023-04766-3. Epub 2023 Apr 17. J Cancer Res Clin Oncol. 2023. PMID: 37067546
The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study.
Guven DC, Acar R, Yekeduz E, Bilgetekin I, Baytemur NK, Erol C, Ceylan F, Sendur MA, Demirci U, Urun Y, Karadurmus N, Erman M, Kilickap S. Guven DC, et al. Among authors: yekeduz e. Curr Probl Cancer. 2021 Dec;45(6):100760. doi: 10.1016/j.currproblcancer.2021.100760. Epub 2021 Jun 5. Curr Probl Cancer. 2021. PMID: 34130864
Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study.
Başoğlu T, Sakin A, Erol C, Özden E, Çabuk D, Çılbır E, Tataroğlu Özyükseler D, Ayhan M, Şendur MA, Dogan M, Öksüzoğlu B, Eryılmaz MK, Er Ö, Taşçı EŞ, Özyurt N, Dülgar Ö, Özen M, Hacıbekiroğlu İ, Öner İ, Bekmez ET, Çağrı Yıldırım H, Yalçın Ş, Paydaş S, Yekedüz E, Aksoy A, Özçelik M, Oyman A, Almuradova E, Karabulut B, Demir N, Dinçer M, Özdemir N, Erdem D, Ak N, İnal A, Salim DK, Deniz Gİ, Şakalar T, Gülmez A, Kaçan T, Özdemir Ö, Alan Ö, Ünal Ç, Karakaş Y, Turhal S, Yumuk PF. Başoğlu T, et al. Among authors: yekeduz e. J Chemother. 2023 Apr;35(2):142-149. doi: 10.1080/1120009X.2022.2073159. Epub 2022 May 17. J Chemother. 2023. PMID: 35579894
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.
Yekedüz E, Tural D, Ertürk İ, Karakaya S, Erol C, Ercelep Ö, Arslan Ç, Sever ÖN, Kılıçkap S, Şentürk Öztaş N, Küçükarda A, Can O, Öksüzoğlu B, Şendur MA, Karadurmuş N, Ürün Y. Yekedüz E, et al. J Cancer Res Clin Oncol. 2022 Dec;148(12):3537-3546. doi: 10.1007/s00432-022-04055-5. Epub 2022 May 26. J Cancer Res Clin Oncol. 2022. PMID: 35616728
External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.
Yekedüz E, Karakaya S, Ertürk İ, Tural D, Uçar G, Şentürk Öztaş N, Arıkan R, Hızal M, Küçükarda A, Sever ÖN, Arslan Ç, Can O, Kılıçkap S, Yazgan C, Karadurmuş N, Şendur MA, Çiçin İ, Demirci U, Özgüroğlu M, Öksüzoğlu B, Ürün Y. Yekedüz E, et al. Clin Genitourin Cancer. 2023 Feb;21(1):175-182. doi: 10.1016/j.clgc.2022.07.006. Epub 2022 Jul 16. Clin Genitourin Cancer. 2023. PMID: 35970759
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study.
Yekedüz E, Özbay MF, Çağlayan D, Yıldırım A, Erol C, Yıldırım HÇ, Tunç S, Özyurt N, Özdemir F, Şendur MAN, Işıkdoğan A, Kılıçkap S, Ürün Y, Yalçın Ş, Artaç M, Coşkun HŞ, Utkan G. Yekedüz E, et al. Eur J Clin Pharmacol. 2022 Dec;78(12):1973-1979. doi: 10.1007/s00228-022-03403-1. Epub 2022 Oct 21. Eur J Clin Pharmacol. 2022. PMID: 36266366
Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium.
Erol C, Yekedüz E, Tural D, Karakaya S, Şentürk Öztaş N, Uçar G, Kılıçkap S, Ertürk İ, Sever ÖN, Arslan Ç, Küçükarda A, Can O, Balvan Ö, Yazgan SC, Özgüroğlu M, Öksüzoğlu B, Şendur MAN, Ürün Y. Erol C, et al. Among authors: yekeduz e. Urol Int. 2023;107(6):595-601. doi: 10.1159/000528994. Epub 2023 Mar 30. Urol Int. 2023. PMID: 36996793
The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
Almuradova E, Seyyar M, Arak H, Tamer F, Kefeli U, Koca S, Sen E, Telli TA, Karatas F, Gokmen I, Turhal NS, Sakalar T, Ayhan M, Ekinci F, Hafizoglu E, Kahraman S, Kesen O, Unal C, Alan O, Celik S, Yekeduz E, Omur O, Gokmen E. Almuradova E, et al. Among authors: yekeduz e. Int J Cancer. 2024 Feb 15;154(4):692-700. doi: 10.1002/ijc.34749. Epub 2023 Oct 11. Int J Cancer. 2024. PMID: 37818966
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
Yekedüz E, Ertürk İ, Tural D, Karadurmuş N, Karakaya S, Hızal M, Arıkan R, Arslan Ç, Taban H, Küçükarda A, Öztaş NŞ, Sever ÖN, Uçar G, Can O, Şendur MA, Demirci U, Kılıçkap S, Çiçin İ, Öksüzoğlu B, Özgüroğlu M, Ürün Y. Yekedüz E, et al. Future Oncol. 2021 Dec;17(35):4861-4869. doi: 10.2217/fon-2021-0717. Epub 2021 Nov 2. Future Oncol. 2021. PMID: 34726480
47 results